Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ATEZOLIZUMAB Cause Intentional product use issue? 740 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 740 reports of Intentional product use issue have been filed in association with ATEZOLIZUMAB (Tecentriq Hybreza). This represents 2.2% of all adverse event reports for ATEZOLIZUMAB.

740
Reports of Intentional product use issue with ATEZOLIZUMAB
2.2%
of all ATEZOLIZUMAB reports
285
Deaths
191
Hospitalizations

How Dangerous Is Intentional product use issue From ATEZOLIZUMAB?

Of the 740 reports, 285 (38.5%) resulted in death, 191 (25.8%) required hospitalization, and 21 (2.8%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ATEZOLIZUMAB. However, 740 reports have been filed with the FAERS database.

What Other Side Effects Does ATEZOLIZUMAB Cause?

Death (3,591) Off label use (2,340) Disease progression (1,828) Pyrexia (1,599) Diarrhoea (1,490) Fatigue (1,253) Anaemia (1,195) Pneumonia (1,036) Nausea (953) Dyspnoea (938)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which ATEZOLIZUMAB Alternatives Have Lower Intentional product use issue Risk?

ATEZOLIZUMAB vs ATLANTIC SALMON OIL ATEZOLIZUMAB vs ATOGEPANT ATEZOLIZUMAB vs ATOMOXETINE ATEZOLIZUMAB vs ATOMOXETINE\ATOMOXETINE ATEZOLIZUMAB vs ATORVASTATIN

Related Pages

ATEZOLIZUMAB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue ATEZOLIZUMAB Demographics